Business Description
LAVA Therapeutics NV
ISIN : NL0015000AG6
Description
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 213.32 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.17 | |||||
| Beneish M-Score | -4.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.2 | |||||
| 3-Year EBITDA Growth Rate | 25 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 21.2 | |||||
| 3-Year Book Growth Rate | -38.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 29.18 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.25 | |||||
| 9-Day RSI | 72.96 | |||||
| 14-Day RSI | 67.31 | |||||
| 3-1 Month Momentum % | -5.98 | |||||
| 6-1 Month Momentum % | 22.91 | |||||
| 12-1 Month Momentum % | -39.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.73 | |||||
| Quick Ratio | 6.73 | |||||
| Cash Ratio | 6.42 | |||||
| Days Sales Outstanding | 45.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 4.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -708.02 | |||||
| Net Margin % | -561.94 | |||||
| EBITDA Margin % | -490.84 | |||||
| FCF Margin % | -586.38 | |||||
| ROE % | -77.86 | |||||
| ROA % | -32.86 | |||||
| ROIC % | -505.72 | |||||
| 3-Year ROIIC % | -609.81 | |||||
| ROC (Joel Greenblatt) % | -1470.18 | |||||
| ROCE % | -35.31 | |||||
| Moat Score | 5 | |||||
| Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.74 | |||||
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.51 | |||||
| EV-to-EBIT | 1.09 | |||||
| EV-to-EBITDA | 1.12 | |||||
| EV-to-Revenue | -5.5 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | 0.93 | |||||
| Price-to-GF-Value | 1.55 | |||||
| Price-to-Net-Current-Asset-Value | 1.59 | |||||
| Price-to-Net-Cash | 1.82 | |||||
| Earnings Yield (Greenblatt) % | 91.38 | |||||
| FCF Yield % | -78.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LAVA Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.765 | ||
| EPS (TTM) (€) | -0.956 | ||
| Beta | -0.01 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.02 | ||
| Volatility % | 61.74 | ||
| 14-Day RSI | 67.31 | ||
| 14-Day ATR (€) | 0.031944 | ||
| 20-Day SMA (€) | 1.1575 | ||
| 12-1 Month Momentum % | -39.56 | ||
| 52-Week Range (€) | 0.86 - 1.92 | ||
| Shares Outstanding (Mil) | 26.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LAVA Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LAVA Therapeutics NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
LAVA Therapeutics NV Frequently Asked Questions
What is LAVA Therapeutics NV(FRA:4PKB)'s stock price today?
The current price of FRA:4PKB is €1.24. The 52 week high of FRA:4PKB is €1.92 and 52 week low is €0.86.
When is next earnings date of LAVA Therapeutics NV(FRA:4PKB)?
The next earnings date of LAVA Therapeutics NV(FRA:4PKB) is 2025-08-20 Est..
Does LAVA Therapeutics NV(FRA:4PKB) pay dividends? If so, how much?
LAVA Therapeutics NV(FRA:4PKB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers